Vectorology and factor delivery in induced pluripotent stem cell reprogramming

Stem Cells and Development

Volumn 23, Issue 12, 2014, Pages 1301-1315

  Hu, Kejin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVIRUS VECTOR; BACTERIAL DNA; CIRCULAR DNA; CRE RECOMBINASE; EPSTEIN BARR VIRUS ANTIGEN 1; LENTIVIRUS VECTOR; MINICIRCLE DNA; PLASMID VECTOR; RETROVIRUS VECTOR; RNA; SENDAI VIRUS VECTOR; UNCLASSIFIED DRUG; TRANSPOSON;

CISTRON; EPISOMAL VECTOR; EPISOME; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; EXPRESSION VECTOR; GENETIC TRANSFECTION; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LOXP SITE; NONHUMAN; NUCLEAR REPROGRAMMING; PIGGYBAC TRANSPOSON; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSDUCTION; REPLICON; REVIEW; SENDAI VIRUS; TRANSPOSON; VIRUS PARTICLE; CELL DIFFERENTIATION; CULTURE TECHNIQUE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; PROCEDURES; RETROVIRUS;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; DNA TRANSPOSABLE ELEMENTS; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTAGENESIS, INSERTIONAL; RETROVIRIDAE; TRANSFECTION;

EID: 84902214868     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0621     Document Type: Review

References (128)

1. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
2. Yu J, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, JL Frane, S Tian, J Nie, GA Jonsdottir, V Ruotti, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920.
3. Hu K and I Slukvin. (2012). Induction of pluripotent stem cells from umbilical cord blood. In: Encyclopedia of Molecular Cell Biology and Molecular Medicine: Stem Cells. RA Meyers, ed. Wiley-VCH Verlag GmbH &Co. KGaA., pp 1-25. DOI: 10.1002/3527600906.mcb.2012 00006.
4. Yu J, K Hu, K Smuga-Otto, S Tian, R Stewart, II Slukvin and JA Thomson. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324:797-801.
5. Hu K, J Yu, K Suknuntha, S Tian, K Montgomery, KD Choi, R Stewart, JA Thomson and II Slukvin. (2011). Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 117:e109-e119.
6. Hu K and I Slukvin. (2013). Generation of transgenefree iPSC lines from human normal and neoplastic blood cells using episomal vectors. Methods Mol Biol 997: 163-176.
7. Stadtfeld M, M Nagaya, J Utikal, G Weir and K Hochedlinger. (2008). Induced pluripotent stem cells generated without viral integration. Science 322:945-949.
8. Woltjen K, IP Michael, P Mohseni, R Desai, M Mileikovsky, R Hamalainen, R Cowling, W Wang, P Liu, et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766-770.
9. Kaji K, K Norrby, A Paca, M Mileikovsky, P Mohseni and K Woltjen. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458:771-775.
10. Chang CW, YS Lai, KM Pawlik, K Liu, CW Sun, C Li, TR Schoeb and TM Townes. (2009). Polycistronic lentiviral vector for ''Hit and Run'' reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27:1042-1049.
11. Okita K, M Nakagawa, HJ Hong, T Ichisaka and S Yamanaka. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science 322:949-953.
12. Jia F, KD Wilson, N Sun, DM Gupta, M Huang, Z Li, NJ Panetta, ZY Chen, RC Robbins, et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7:197-199.
13. Zhou HY, SL Wu, JY Joo, SY Zhu, DW Han, TX Lin, S Trauger, G Bien, S Yao, et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4:381-384.
14. Warren L, PD Manos, T Ahfeldt, YH Loh, H Li, F Lau, W Ebina, PK Mandal, ZD Smith, et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618-630.
15. Seki T, S Yuasa, M Oda, T Egashira, K Yae, D Kusumoto, H Nakata, S Tohyama, H Hashimoto, et al. (2010). Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7:11-14.
16. Yoshioka N, E Gros, HR Li, S Kumar, DC Deacon, C Maron, AR Muotri, NC Chi, XD Fu, BD Yu and SF Dowdy. (2013). Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 13:246-254.
17. Hu K. (2014). All roads lead to the induced pluripotent stem cells: the technologies of iPSC generation. Stem Cells Dev [Epub ahead of print]; DOI: 10.1089/scd .2013.0620.
18. Walther W and U Stein. (2000). Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60:249-271.
19. Cepko C and W Pear. (1996). Overview of the retrovirus transduction system. In: Current Protocols in Molecular Biology. FM Ausubel, R Brent, RE Kingston, DD Moore, JG Seidman, JA Smith, K Struhl, eds. John Wiley &Sons, Inc., USA, pp 9.9.1-9.9.16.
20. Takahashi K, K Tanabe, M Ohnuki, M Narita, T Ichisaka, K Tomoda and S Yamanaka. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.
21. Goff SP. (2007). Retroviridea: The Retroviruses and Their Replication. In: Fields' Virology. DM Knipe, PM Howley, eds. Tolters Kluwer Health/Lippincott Williams &Wilkins, Philadelphia, PA, pp 1999-2069.
22. Rein A. (2011). Murine leukemia viruses: objects and organisms. Adv Virol 2011:403419.
23. Miller AD. (1996). Cell-surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci U S A 93:11407-11413.
24. Weiss RA and CS Tailor. (1995). Retrovirus receptors. Cell 82:531-533.
25. Friedmann T and JK Yee. (1995). Pseudotyped retroviral vectors for studies of human gene-therapy. Nat Med 1:275-277.
26. Finkelshtein D, A Werman, D Novick, S Barak and M Rubinstein. (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110:7306-7311.
27. Morita S, T Kojima and T Kitamura. (2000). Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7:1063-1066.
28. Pear W. (1996). Transient transfection methods for preparation of high-titer retroviral supernatants. In: Current Protocols in Molecular Biology. FM Ausubel, R Brent, RE Kingston, DD Moore, JG Seidman, JA Smith, K Struhl, eds. John Wiley &Sons, Inc., USA, pp 9.11.11-19.11.18.
29. Miller DG, MA Adam and AD Miller. (1990). Genetransfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239-4242.
30. Roe TY, TC Reynolds, G Yu and PO Brown. (1993). Integration of murine leukemia-virus DNA depends on mitosis. Embo J 12:2099-2108.
31. Wolf D and SP Goff. (2007). TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131:46-57.
32. Wolf D and SP Goff. (2009). Embryonic stem cells use ZFP809 to silence retroviral DNAs. Nature 458:1201-1204.
33. Antoniou MN, KA Skipper and O Anakok. (2013). Optimizing retroviral gene expression for effective therapies. Hum Gene Ther 24:363-374.
34. Hotta A and J Ellis. (2008). Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem 105:940-948.
35. Srinivasakumar N, M Zaboikin, AM Tidball, AA Aboud, MD Neely, KC Ess, AB Bowman and FG Schuening. (2013). Gammaretroviral vector encoding a fluorescent marker to facilitate detection of reprogrammed human fibroblasts during iPSC generation. Peer J 1:e224.
36. Federico M. (2003). From lentiviruses to lentivirus vectors. Methods Mol Biol 229:3-15.
37. Marino MP, MJ Luce and J Reiser. (2003). Small-to large-scale production of lentivirus vectors. Methods Mol Biol 229:43-55.
38. Lotti F and F Mavilio. (2003). The choice of a suitable lentivirus vector: transcriptional targeting. Methods Mol Biol 229:17-27.
39. Follenzi A and L Naldini. (2002). Generation of HIV-1 derived lentiviral vectors. Method Enzymol 346:454-465.
40. Freed EO and MA Martin. (2007). HIVs and their replication. In: Fields' Virology. DM Knipe, PM Howley, eds. LippincottWilliams &Wilkins, Philadelphia, pp 2107-2185.
41. Schambach A, D Zychlinski, B Ehrnstroem and C Baum. (2013). Biosafety features of lentiviral vectors. Hum Gene Ther 24:132-142.
42. Kutner RH, XY Zhang and J Reiser. (2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4:495-505.
43. Pacchia AL, S Mukherjee and JP Dougherty. (2003). Choice and use of appropriate packaging cell types. Methods Mol Biol 229:29-42.
44. Broussau S, N Jabbour, G Lachapelle, Y Durocher, R Tom, J Transfiguracion, R Gilbert and B Massie. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16:500-507.
45. Fassati A. (2006). HIV infection of non-dividing cells: a divisive problem. Retrovirology 3:74.
46. Li LH and H Clevers. (2010). Coexistence of quiescent and active adult stem cells in mammals. Science 327:542-545.
47. Chen ZY, CY He, L Meuse and MA Kay. (2004). Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 11:856-864.
48. Chen ZY, CY He, A Ehrhardt and MA Kay. (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8:495-500.
49. Kay MA, CY He and ZY Chen. (2010). A robust system for production of minicircle DNA vectors. Nat Biotechnol 28:1287-1289.
50. Bigger BW, O Tolmachov, JM Collombet, M Fragkos, I Palaszewski and C Coutelle. (2001). An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 276:23018-23027.
51. Nehlsen K, S Broll and J Bode. (2006). Replicating minicircles: generation of nonviral episomes for the efficient modification of dividing cells-Research article. Gene Ther Mol Biol 10B:233-243.
52. Mayrhofer P, M Blaesen, M Schleef and W Jechlinger. (2008). Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 10:1253-1269.
53. Matsushita M and H Matsui. (2005). Protein transduction technology. J Mol Med (Berl) 83:324-328.
54. Noguchi H, M Matsushita, N Kobayashi, MF Levy and S Matsumoto. (2010). Recent advances in protein transduction technology. Cell Transplant 19:649-654.
55. Noguchi H and S Matsumoto. (2006). Protein transduction technology: a novel therapeutic perspective. Acta Med Okayama 60:1-11.
56. El-Sayed A, S Futaki and H Harashima. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. Aaps J 11:13-22.
57. Wadia JS and SF Dowdy. (2002). Protein transduction technology. Curr Opin Biotechnol 13:52-56.
58. Kim D, CH Kim, JI Moon, YG Chung, MY Chang, BS Han, S Ko, E Yang, KY Cha, R Lanza and KS Kim. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4:472-476.
59. Frankel AD and CO Pabo. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193.
60. Dowdy SF. (2005). Protein transduction: generation of fulllength transducible proteins using the TAT system. In: Current Protocols in Cell Biology. JS Bonifacino, M Dasso, JB Harford, J Lippincott-Schwartz, KM Yamada, eds. John Wiley &Sons, Inc., Bethesda, MD, pp 20.22.21-20.22.25.
61. Vives E, P Brodin and B Lebleu. (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017.
62. Elliott G and P O'Hare. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-233.
63. Derossi D, AH Joliot, G Chassaing and A Prochiantz. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450.
64. Pietersz GA, W Li and V Apostolopoulos. (2001). A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway. Vaccine 19:1397-1405.
65. Richard JP, K Melikov, E Vives, C Ramos, B Verbeure, MJ Gait, LV Chernomordik and B Lebleu. (2003). Cellpenetrating peptides-A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585-590.
66. Heitz F, MC Morris and G Divita. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195-206.
67. Schwarze SR, A Ho, A Vocero-Akbani and SF Dowdy. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569-1572.
68. Futaki S, T Suzuki, W Ohashi, T Yagami, S Tanaka, K Ueda and Y Sugiura. (2001). Arginine-rich peptides-An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836-5840.
69. Walev I, SC Bhakdi, F Hofmann, N Djonder, A Valeva, K Aktories and S Bhakdi. (2001). Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A 98: 3185-3190.
70. Agarwal S. (2006). Cellular reprogramming. Method Enzymol 420:265-283.
71. Cho HJ, CS Lee, YW Kwon, JS Paek, SH Lee, J Hur, EJ Lee, TY Roh, IS Chu, et al. (2010). Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 116:386-395.
72. Lamb RA and GD Parks. (2007). Paramyxoviridae: The viruses and their replcation. In: Fields Virology. DM Knipe, PM Howley, eds. Lippincott Williams &Wilkins, Philadelphia, PA, pp 1449-1496.
73. Bitzer M, S Armeanu, UM Lauer and WJ Neubert. (2003). Sendai virus vectors as an emerging negativestrand RNA viral vector system. J Gene Med 5:543-553.
74. Hasan MK, A Kato, T Shioda, Y Sakai, DS Yu and Y Nagai. (1997). Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3¢ proximal first locus. J Gen Virol 78:2813-2820.
75. Yoshizaki M, T Hironaka, H Iwasaki, H Ban, Y Tokusumi, A Iida, Y Nagai, M Hasegawa and M Inoue. (2006). Naked Sendai virus vector tacking all of the enveloperelated genes: reduced cytopathogenicity and immunogenicity. J Gene Med 8:1151-1159.
76. Nishimura K, M Sano, M Ohtaka, B Furuta, Y Umemura, Y Nakajima, Y Ikehara, T Kobayashi, H Segawa, et al. (2011). Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 286:4760-4771.
77. Li HO, YF Zhu, M Asakawa, H Kuma, T Hirata, Y Ueda, YS Lee, M Fukumura, A Iida, et al. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74:6564-6569.
78. Inoue M, Y Tokusumi, H Ban, T Kanaya, T Tokusumi, Y Nagai, A Iida and M Hasegawa. (2003). Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 77:3238-3246.
79. Ban H, N Nishishita, N Fusaki, T Tabata, K Saeki, M Shikamura, N Takada, M Inoue, M Hasegawa, S Kawamata and S Nishikawa. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 108:14234-14239.
80. Fusaki N, H Ban, A Nishiyama, K Saeki and M Hasegawa. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85:348-362.
81. Malone RW, PL Felgner and IM Verma. (1989). Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A 86:6077-6081.
82. Bringmann A, SA Held, A Heine and P Brossart. (2010). RNA vaccines in cancer treatment. J Biomed Biotechnol 2010:623687.
83. Nguyen J and FC Szoka (2012). Nucleic acid delivery: the missing pieces of the puzzle? Acc Chem Res 45 1153-1162.
84. Weide B, C Garbe, HG Rammensee and S Pascolo. (2008). Plasmid DNA-and messenger RNA-based anticancer vaccination. Immunol Lett 115:33-42.
85. Gallie DR. (1991). The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev 5:2108-2116.
86. Sclimenti CR and MP Calos. (1998). Epstein-Barr virus vectors for gene expression and transfer. Curr Opin Biotechnol 9:476-479.
87. Van Craenenbroeck K, P Vanhoenacker and G Haegeman. (2000). Episomal vectors for gene expression in mammalian cells. Eur J Biochem 267:5665-5678.
88. Lindner SE and B Sugden. (2007). The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 58:1-12.
89. Yates JL, N Warren and B Sugden. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812-815.
90. Yates J, N Warren, D Reisman and B Sugden. (1984). A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 81:3806-3810.
91. Reisman D, J Yates and B Sugden. (1985). A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 5:1822-1832.
92. Yates JL, SM Camiolo and JM Bashaw. (2000). The minimal replicator of Epstein-Barr virus oriP. J Virol 74:4512-4522.
93. Kirchmaier AL and B Sugden. (1995). Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 69:1280-1283.
94. Mizuguchi H, T Hosono and T Hayakawa. (2000). Longterm replication of Epstein-Barr virus-derived episomal vectors in the rodent cells. FEBS Lett 472:173-178.
95. de Felipe P. (2004). Skipping the co-expression problem: the new 2A ''CHYSEL'' technology. Genet Vaccines Ther 2:13.
96. de Felipe P, GA Luke, LE Hughes, D Gani, C Halpin and MD Ryan. (2006). E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol 24:68-75.
97. Szymczak-Workman AL, KM Vignali and DA Vignali. (2012). Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb Protoc 2012:199-204.
98. Kim JH, SR Lee, LH Li, HJ Park, JH Park, KY Lee, MK Kim, BA Shin and SY Choi. (2011). High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6:e18556.
99. Donnelly MLL, LE Hughes, G Luke, H Mendoza, E ten Dam, D Gani and MD Ryan. (2001). The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 82:1027-1041.
100. de Felipe P, GA Luke, JD Brown and MD Ryan. (2010). Inhibition of 2A-mediated 'cleavage' of certain artificial polyproteins bearing N-terminal signal sequences. Biotechnol J 5:213-223.
101. Belsham GJ. (2009). Divergent picornavirus IRES elements. Virus Res 139:183-192.
102. Jackson RJ and A Kaminski. (1995). Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond. RNA 1:985-1000.
103. Houdebine LM and J Attal. (1999). Internal ribosome entry sites (IRESs): reality and use. Transgenic Res 8:157-177.
104. Pelletier J and N Sonenberg. (1988). Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320-325.
105. Mizuguchi H, ZL Xu, A Ishii-Watabe, E Uchida and T Hayakawa. (2000). IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1:376-382.
106. Ding S, X Wu, G Li, M Han, Y Zhuang and T Xu. (2005). Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122:473-483.
107. Mitra R, J Fain-Thornton and NL Craig. (2008). piggyBac can bypass DNA synthesis during cut and paste transposition. Embo J 27:1097-1109.
108. Wu SCY, YJJ Meir, CJ Coates, AM Handler, P Pelczar, S Moisyadi and JM Kaminski. (2006). piggyBac is a flexible and highly active transposon as compared to Sleeping Beauty, Tol2 and Mos1 in mammalian cells. Proc Natl Acad Sci U S A 103:15008-15013.
109. Handler AM. (2002). Use of the piggyBac transposon for germ-line transformation of insects. Insect Biochem Molec 32:1211-1220.
110. Feschotte C. (2006). The piggyBac transposon holds promise for human gene therapy. Proc Natl Acad Sci U S A 103:14981-14982.
111. Kim A and I Pyykko. (2011). Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool. Mol Cell Biochem 354:301-309.
112. Li X, RA Harrell, AM Handler, T Beam, K Hennessy and MJ Fraser, Jr. (2005). piggyBac internal sequences are necessary for efficient transformation of target genomes. Insect Mol Biol 14:17-30.
113. Yusa K, R Rad, J Takeda and A Bradley. (2009). Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 6:363-369.
114. McConnell MJ and MJ Imperiale. (2004). Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15:1022-1033.
115. Russell WC. (2000). Update on adenovirus and its vectors. J Gen Virol 81:2573-2604.
116. Zhang WW. (1999). Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 6:113-138.
117. Danthinne X and MJ Imperiale. (2000). Production of first generation adenovirus vectors: a review. Gene Ther 7:1707-1714.
118. Alba R, A Bosch and M Chillon. (2005). Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12 Suppl 1:S18-S27.
119. Harui A, S Suzuki, S Kochanek and K Mitani. (1999). Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73:6141-6146.
120. Strauss JH and EG Strauss. (1994). The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491-562.
121. Hahn CS, YS Hahn, TJ Braciale and CM Rice. (1992). Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A 89:2679-2683.
122. Xiong C, R Levis, P Shen, S Schlesinger, CM Rice and HV Huang. (1989). Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188-1191.
123. Herweijer H, JS Latendresse, P Williams, GF Zhang, I Danko, S Schlesinger and JA Wolff. (1995). A plasmidbased self-amplifying sindbis-virus vector. Hum Gene Ther 6:1161-1167.
124. Dubensky TW, DA Driver, JM Polo, BA Belli, EM Latham, CE Ibanez, S Chada, D Brumm, TA Banks, et al. (1996). Sindbis virus DNA-based expression vectors: Utility for in vitro and in vivo gene transfer. J Virol 70:508-519.
125. DiCiommo DP and R Bremner. (1998). Rapid, high level protein production using DNA-based semliki forest virus vectors. J Biol Chem 273:18060-18066.
126. Petrakova O, E Volkova, R Gorchakov, S Paessler, RM Kinney and I Frolov. (2005). Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in mammalian cells. J Virol 79:7597-7608.
127. Agapov EV, I Frolov, BD Lindenbach, BM Pragai, S Schlesinger and CM Rice. (1998). Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci U S A 95:12989-12994.
128. Golipour A, L David, Y Liu, G Jayakumaran, CL Hirsch, D Trcka and JL Wrana. (2012). A late transition in somatic cell reprogramming requires regulators distinct from the pluripotency network. Cell Stem Cell 11: 769-782.